Share This Link

Acetaminophen: Acetaminophen is commonly used for pain relief and fever reduction and does not typically interact significantly with morphine. However, it is essential to assess the client's total acetaminophen intake from all sources to prevent exceeding the maximum recommended daily dose and minimize the risk of hepatotoxicity.

Ondansetron: Ondansetron is an antiemetic medication commonly used to prevent nausea and vomiting, particularly in clients receiving opioid analgesics. It does not typically interact significantly with morphine and can be safely administered concurrently.

Insulin glargine: Insulin glargine is a long-acting insulin used to control blood glucose levels in clients with diabetes mellitus. It does not interact significantly with morphine and can be safely administered concurrently. However, close monitoring of blood glucose levels is necessary in clients receiving both insulin and opioids due to the potential for opioid-induced hyperglycemia.

Return the remaining medication to the facility's pharmacy: Returning the remaining medication to the pharmacy is not appropriate in this situation because the medication has been removed from its original packaging and administered to the patient. Once medication has been removed from its original packaging and administered, it cannot be returned to the pharmacy for reuse or storage due to contamination risks and potential medication errors.

Store the remaining half of the pill in the automated medication dispensing system: Storing the remaining half of the pill in the automated medication dispensing system is not appropriate because the medication has already been removed from its original packaging and administered to the patient. Storing half tablets in the automated dispensing system could lead to medication errors and confusion during future administrations.

Place the remaining half of the pill in the unit-dose package: Placing the remaining half of the pill in the unit-dose package is not appropriate because the medication has already been removed from its original packaging and administered to the patient. Placing half tablets back into the unit-dose package could lead to medication errors and confusion during future administrations.

Urine output: While urine output is an essential assessment in many clinical situations, it is not the primary parameter for titrating a nitroprusside infusion. Nitroprusside is primarily used to manage blood pressure, so monitoring urine output alone may not provide adequate information for adjusting the infusion rate.

Stroke volume: Although stroke volume is an important hemodynamic parameter, it is not typically used as the primary indicator for titrating a nitroprusside infusion. Nitroprusside primarily affects systemic vascular resistance and arterial blood pressure rather than directly influencing stroke volume.

Cardiac output: While cardiac output is a vital hemodynamic parameter, it is not the primary focus when titrating a nitroprusside infusion. Nitroprusside primarily affects systemic vascular resistance and arterial blood pressure rather than directly impacting cardiac output. However, changes in blood pressure resulting from nitroprusside administration may indirectly influence cardiac output.

Tinnitus: Tinnitus (ringing in the ears) is not typically associated with interferon therapy. It is more commonly associated with medications such as certain antibiotics, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs).

Paresthesia: Paresthesia (abnormal sensation such as tingling or numbness) is not a common adverse effect of interferon therapy. It is more commonly associated with neurological conditions or peripheral neuropathies.

Oliguria: Oliguria (decreased urine output) is not a typical adverse effect of interferon therapy. It may indicate renal dysfunction or dehydration but is not directly associated with interferon administration.

Bronchospasms: Atropine is not contraindicated in clients with bronchospasms. In fact, it can be used to treat bronchospasms associated with conditions like asthma or chronic obstructive pulmonary disease (COPD) by dilating the airways. Therefore, bronchospasms would not preclude the administration of atropine.

Diverticulitis: Atropine is not contraindicated in clients with diverticulitis. In fact, it can be used to treat symptoms of diverticulitis, such as abdominal cramping, by reducing gastrointestinal motility and spasm. Therefore, diverticulitis would not preclude the administration of atropine.

Diarrhea: Atropine can be used to treat diarrhea by reducing gastrointestinal motility and secretions. Therefore, diarrhea would not be a contraindication to administering atropine. In fact, atropine can be included in medications used to manage diarrhea, especially if it's associated with increased gastrointestinal motility.

A client receives their meal tray 20 minutes late: While it's not ideal for a client to receive their meal late, this situation does not typically require an incident report unless there are extenuating circumstances or if the delay significantly impacts the client's health or well-being. However, it's important to document the delay in the client's chart for accurate record-keeping and to ensure appropriate follow-up.

A client vomits after receiving an oral medication: This situation may warrant an incident report. Vomiting after receiving medication could indicate a potential adverse reaction or intolerance to the medication. An incident report would document the event, including details such as the medication administered, the time of administration, the client's response, and any subsequent interventions. This information is crucial for identifying trends, ensuring proper follow-up care, and preventing similar incidents in the future.

A client experiences a seizure: Seizures are significant events that typically require immediate attention and intervention. While an incident report may be initiated after the seizure episode, the priority is to ensure the client's safety and provide appropriate medical care during and after the seizure. The focus should be on assessing the client, implementing seizure precautions if necessary, and administering any prescribed rescue medications or treatments as indicated.

Reason: The reason for prescribing ondansetron (Zofran) is not typically included in the prescription itself but should be documented in the client's medical record. Ondansetron is commonly prescribed to prevent or treat nausea and vomiting associated with chemotherapy, radiation therapy, surgery, or gastroenteritis.

Route: The route of administration is clearly stated in the prescription as "by mouth" (PO), indicating that the medication should be taken orally. Since the route is specified, there is no need for clarification with the provider regarding this aspect of the prescription.

Dose: The prescribed dose of ondansetron is 8 mg, which is clearly stated in the prescription. The nurse should verify that the dose is appropriate for the client's condition and aligns with institutional protocols for administering ondansetron. Since the dose is explicitly provided, there is no need for clarification with the provider regarding this aspect of the prescription.

Abdominal cramping: Abdominal cramping can have various causes, including gastrointestinal issues, but it is not specific to warfarin therapy. While abdominal cramping should be assessed and addressed, it is not as urgent as the potential sign of bleeding indicated by melena.

Fever: Fever may indicate an infection or another underlying condition but is not directly related to warfarin therapy. While it should be assessed and reported if persistent or accompanied by other concerning symptoms, it is not the priority finding in this context.

Hair loss: Hair loss is not a common or significant side effect of warfarin therapy. While it may be distressing for the client, it is not typically a priority finding to report to the provider unless it is severe or accompanied by other concerning symptoms.

Have the client take the medication on an empty stomach to avoid interactions:This action may not be appropriate as taking medications on an empty stomach can sometimes increase the risk of adverse effects or decrease medication effectiveness. The decision to take medication with or without food depends on the specific medication and its instructions. It does not address the broader scope of potential interactions with other medications or foods.

Ask another nurse if they are aware of potential interactions:
While seeking advice from colleagues can sometimes be helpful, relying solely on another nurse's knowledge may not provide comprehensive information about potential interactions. Additionally, the accuracy and reliability of the information obtained from another nurse may vary. Consulting a drug reference guide or other reliable resources is a more systematic approach to ensuring medication safety.

Check the client's medical record for medication and food interactions:While the client's medical record may contain valuable information about their current medications and medical history, it may not always include detailed information about potential interactions with specific foods. Additionally, relying solely on the medical record may overlook recent changes in the client's medication regimen or newly prescribed medications. Consulting a drug reference guide provides more comprehensive and up-to-date information about potential interactions.

Massage the injection site after administering the medication:Massaging the injection site after administering enoxaparin or any other medication is not recommended. It could potentially disrupt the absorption of the medication or cause tissue damage at the injection site. Therefore, this action is incorrect.

Hold the skin taut at the injection site while administering the medication:Holding the skin taut at the injection site is not necessary for administering enoxaparin. Unlike some intramuscular injections, enoxaparin is typically administered subcutaneously, and holding the skin taut may not be required. This action is unnecessary and not part of the standard procedure for administering enoxaparin.

Expel the air bubble from the syringe prior to administering the medication:While expelling air bubbles from the syringe is a standard practice when preparing medications for injection, it is not specifically related to the administration of enoxaparin. However, ensuring that the syringe is free of air bubbles before injection is still important to prevent air embolism or inaccurate dosing. Therefore, while this action is generally appropriate, it does not address the specific administration technique for enoxaparin.